The U.S. Food and Drug Administration rejected Orphazyme’s key drug candidate for Niemann-Pick disease type C (NPC), causing the Denmark-based biopharmaceutical company’s “meme stock” to decline in trading.
If you are not happy with the results below please do another search
50 search results for:
Bristol Myers Squibb and Eisai forged a strategic collaboration that could be worth nearly $2.5 billion to jointly develop MORAb-202, an antibody drug conjugate (ADC) to be used against certain solid tumors across several different cancer types.
The Delta variant of Covid-19 – first identified in India – is becoming the globally dominant variant of the disease, the World Health Organization’s chief scientist said on June 18.
Data from clinical trials of three experimental Alzheimer’s disease drugs expected to start emerging during 2022 could help shed light on whether U.S. regulators were justified in their controversial approval of a Biogen Inc. treatment without clear evidence that Aduhelm works.
Coronavirus-related deaths worldwide passed a grim milestone of 4 million on June 17, according to a Reuters tally, as many countries struggle to procure enough vaccines to inoculate their populations.
A study from the Icahn School of Medicine at Mount Sinai shows how cancer can fool immune cells, which normally repair the body, into actually helping develop the disease.
Craig Lipset, a clinical trials industry innovator and leader, joined the MedVector team as a new board member and executive advisor.
AbelsonTaylor promoted former content strategist and copy supervisor Tarah Sperando to associate creative director. Sperando will oversee copy teams on assigned brands and projects, helping to implement novel creative solutions and develop new strategies for meeting client marketing goals. She will also participate in brand planning, market research, and new business development.
The U.S. Food and Drug Administration approved Blueprint Medicines’ Ayvakit (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis.
Biogen’s quest to develop additional medicines for Alzheimer’s disease beyond the company’s newly approved aducanumab hit a clinical snag as the anti-tau antibody gosuranemab failed to meet endpoints in a Phase II study and was discontinued.